Human calcitonin (hCT) like material has been detected in plasma, urine and tissue extracts of patients with medullary thyroid carcinoma (MTC) and lung cancer as well as in the incubation medium of cultured cells of these tumours (Bertagna et al., 1978; Ellison et al., 1975; Goltzman & Tischler, 1978; Goltzman et al., 1974; Gropp et al., 1980a,b; Ham et al., 1980; Luster et al., 1982; Milhaud et al., 1974; Silva et al., 1974; Sizemore & Heath, 1975) . The hCT immunoreactive material has been shown to be useful as tumour markers in patients with MTC and with small cell lung cancer (SCLC) to determine prognosis and response to therapy (Goltzman et al., 1974; Gropp et al., 1980a,b) . The hCT has not only been detected in man but also in protochordates (Galan et al., 1981a , Girgis et al., 1980 , in amphibia (Galan Galan et al., 1981b , Perez Cano et al., 1981 and in birds (Perez Cano et al., 1982) . In these animals hCT coexists with other calcitonins like salmon calcitonin (sCT). Recently the existence of sCT in human thyroid and brain has been described by Fischer et al., 1983 . This study shows for the first time the coexistence of both hCT-and sCTlike material in sera of patients with SCLC and in the culture medium of established lung cancer cell lines.
hCT and sCT were determined simultaneously in about 100 patients with histologically proven SCLC before therapy. Prior to therapy, extent of disease was determined by physical examination, liver function tests, chest and bone X-rays, bronchoand/or mediastinoscopy, bone marrow examination, ultrasound, computerized tomography and nuclear scans of the bone. confines of the definition of limited disease. Both calcitonins were also assayed in the medium of lung tumour cell lines established in our laboratory . For comparison, the culture medium of our medullary carcinoma cell lines were also studied as well as 18 sera of patients with medullary carcinoma of the thyroid. Permanent cell cultures were established from small cell, large cell, squamous and adeno carcinoma of the lung. All purification steps leading to a permanent cell line were controlled by cytological analysis. Cell hCT was determined by means of a commercial radioimmunoassay using an antiserum against synthetic hCT (1-32) as described previously (Luster et al., 1982) . sCT was determined by a radioimmunoassay using an antiserum against sCT (16-32) which showed no cross reactivity against hCT. The double antibody radioimmunoassay was obtained from Diagnostik System Laboratories (Webster, Texas) and is not available commercially.
For further characterization of the hCT-and sCT-like material the incubation medium of two small cell lung cancer cell lines was subjected to gel chromatography and the fractions were assayed simultaneously for hCT and sCT. For this study 3 ml samples of culture medium were subjected to gel filtration on a 1.5 x 90cm column of ACA 54 (LKB Stockholm, Sweden), equilibrated with 80 mM KH2PO4, 0.4M EDTA and 0.1% NaN3, pH 7.4, or with the same buffer containing proteinase inhibitors. Protein was eluted in the presence of the above buffers under a flow rate of 8 ml h-1. Four ml fractions were collected, lyophilized and resuspended in 400p1 of distilled water in order to estimate calcitonin. The column was calibrated with blue dextran (Pharmacia, Uppsala, Sweden), aldolase (Boehringer Mannheim, FRG), bovine serum albumin, ovalbumin, chymotrypsinogen A (Pharmacia, Uppsala, Sweden), myoglobin whale, cytochrome, c, cyanocobalamin, bromophenol-blue (Serva, Heidelberg, FRG) and [1251]-calcitonin (Immunonuclear, Stillwater, MN).
hCT-immunoreactive material was elevated (> 100pgml-'1) in 20/101 (20%) patients with SCLC compared to age and sex matched controls. In 54 (53%) of these patients elevated sCT-immunoreactive material (>1 ng ml -1) was found ( Figure  la) . There was no correlation between the calcitonins in patients sera. As shown in Figure lb , elevated sCT immunoreactivity was seen in patients with low as well as with high hCT immunoreactivity.
Concerning the stage of disease hCT-immunoreactive material was elevated in 18% of patients with limited disease and in 34% of patients with extensive disease. For sCT-like material the frequency was 33% (limited disease) and 40% (extensive disease) (Figure 2) .
High amounts of the sCT-like material could be detected in the incubation medium of several lung cancer cell lines (Figure 3) .
In the medium of the lung cancer cell lines the sCT immunoreactivity was higher than the hCTimmunoreactivity. In contrast, in the medium of the medullary carcinoma cell lines hCT-immunoreactivity was higher than the sCT-immunoreactivity. The same trend was found in sera of 18 patients with medullary carcinoma. Here hCT was elevated in 72%, whereas sCT was only elevated in 39%.
The chromatography results show the presence of three immunoreactive forms of hCT with mol.w of 100,000, 48,000 and 20,000 daltons, all larger than the physiological hCT. These results have been described previously (Luster et al., 1982) . The simultaneous determination of sCT immunoreactivity detected four sCT immunoreactive fractions with mol.w of 100,000, 25,000, 13,000 and 5,000 (Figure 4) .
Our results show for the first time the coexistence of elevated values of hCT-and sCT-like material in the serum of patients with SCLC. It could be demonstrated that both calcitonin immunoreactivities are secreted into the incubation medium by cultured lung cancer cells.
Here, in contrast to studies with medullary carcinoma cells, the values for sCT-like material are higher than for the hCT-like material. The same results were found in vivo where in lung cancer patients the sCT values were higher than the hCT values and in medullary cancer patients vice versa.
Our studies also confirm reports from Fischer et al. (1983) who demonstrated both hCT and sCT in human thyroid and brain. From our studies the nature of the sCT-like material is not clear. From recent investigations of the hCT in lung and medullary cancer patients and from the chromatography studies it can be suggested that we detected by radioimmunoassay an sCT precursor molecule from which the sCT may derive. For hCT-like material high molecular precursor forms with a mol. w in the range from 8,000-55,000 daltons have been isolated from lung and medullary carcinomas (Luster et al., 1982 , Jacobs et al., 1981 Desplan et al., 1980; Roos et al., 1980; Allison et al., 1981) . In any case the sCT-like material may be of further interest as a tumour marker in lung cancer patients. Compared to other tumour markers, the incidence of sCT-immunoreactive material was similar to carcinoembryonic antigen (CEA) and neuron specific enolase (NSE) in patients with SCLC. In this tumour elevated CEA levels have been found in -50% (Concannon et al., 1974 , Vincent et al., 1973 , Gropp et al., 1978 and elevated NSE levels in 45-69% (Gropp et al., unpublished, Carney et al., 1982) . Whereas elevated CEA and NSE values were mostly observed in patients with extensive disease there was no statistical difference for the frequency of sCT-like material in patients with limited or extensive SCLC. So sCT-determination probably may be used in the future concomitantly with other tumour markers in patients with SCLC. In addition, further studies for the biochemical characterization of the higher mol.wt sCT-fractions are on the way. Fractions were assayed for salmon (A) and human (0) calcitonin.
